相对定量real time RT-PCR检测Runx2 mRNA在甲状腺乳头状癌中的表达

Detection of Runx2 mRNA expression using relatively real-time RT-PCR in papillary thyroid carcinoma

目的:相对定量检测Runx2mRNA在甲状腺乳头状癌和腺瘤中的表达,并探讨其在甲状腺乳头状癌的发生发展及与钙化的意义。方法:相对定量real time RT-PCR检测14例甲状腺乳头状癌和14例甲状腺腺瘤中Runx2mRNA的表达。结果:癌组和腺瘤组的ΔCT值分别为2.395±0.302和5.028±1.179,两样本均数差别的t检验示两组之间差异有统计学意义(P<0.01);癌组和腺瘤组的2-ΔΔCT分别为7.826±5.004和1,两样本均数差别的t检验示两组之间差异有统计学意义(P<0.01)。癌组和腺瘤组内以钙化分组ΔCT结果示P>0.05,组间差异均无统计学意义。癌组按肿瘤大小<1cm和≥1cm分组,ΔCT值分别为2.629±0.300和2.212±0.124,P<0.05;2-ΔΔCT值分别为167.33±33.823和221.69±18.843,P<0.01。癌组和腺瘤组以及癌组内钙化分组TSH水平比较均P>0.05。结论:Runx2在甲状腺乳头状癌中的表达高,并与癌大小有关,在较大的癌中表达较高。Runx2与微钙化的关系,可能与甲状腺乳头状癌内钙化灶的产生及癌的发生发展有关,在其他的恶性肿瘤(如乳腺癌、前列腺癌、骨肉瘤)也有相关研究。

Objective：To relatively detect the Runx2 mRNA expression in papillary thyroid carcinoma（PTC） and thyroid adenoma,then to investigate the role of Runx2 in the development and progression in PTC and the relationship with the micro calcification in PTC.Method：The expression of Runx2 mRNA in 14 samples of PTC and 14 samples of thyroid adenoma was examined by relatively real-time RT-PCR.Result：The ΔCT value of the carcinoma group and adenoma group was 2.395±0.302 and 5.028±1.179 respectively（P0.01）.The 2-ΔΔCTvalue of the carcinoma group and adenoma group was 7.826±5.004 and 1 respectively（P0.01）.The carcinoma group was divided into two groups by calcification and there was no statistical difference（P0.05）,and the adenoma group as well.The carcinoma group was divided into two groups by the size of carcinoma（1 cm and ≥1 cm）.The ΔCT value was 2.629±0.300 and 2.212±0.124 respectively（P0.05） and the 2-ΔΔCTvalue was 167.33±33.823 and 221.69±18.843 respectively（P0.01）.The TSH level in carcinoma group and adenoma group had no statistical significance（P0.05）.Conclusion：The expression of Runx2 mRNA was high in PTC,and was related to the size of carcinoma which was higher in bigger size carcinoma.The role of Runx2 may contribute to the formation of the micro-calcification and the development and progression in PTC and other malignant tumors,such as breast cancer,prostatic carcinoma and osteosarcoma.